Pierre Fabre Group History

Founded in the early 1960s by Pierre Fabre, a pharmacist at Castres (Tarn, France), our laboratories have been focusing for more than 50 years on three complementary activities: prescription drugs, health and dermo-cosmetics.

KEY EVENTS

  • 1951: purchase of the Pierre Fabre pharmacy, Jean Jaurès square, Castres (Tarn)
  • 1959: launch of Cyclo 3, a venotonic derived from butcher’s broom (Ruscus aculeatus)
  • 1962: constituent general assembly of Pierre Fabre laboratories
  • 1965: start of the dermo-cosmetic activity
  • 1968: inauguration of the first research center
  • 1970: opening of the first subsidiary in Spain
  • 1974: purchase of the hydrotherapy station at Avène-les-Bains (Hérault)
  • 1989: launch of the anti-cancer drug Navelbine
  • 1990: launch of the Avène Thermal Spring Water brand
  • 1999: creation of the Pierre Fabre Foundation, recognized as being of public utility
  • 2005: opening up of business capital to employees
  • 2010: opening of the R&D center on the Oncopole campus at Toulouse

1950/1960

  • 1951: purchase of the Pierre Fabre pharmacy, Jean Jaurès square, Castres (Tarn)
  • 1959: launch of Cyclo 3, a venotonic derived from butcher’s broom (Ruscus aculeatus)

1960/1970

  • 1961: the success of Cyclo 3 leads Pierre Fabre to create his laboratories
  • 1962: Pierre Fabre Laboratories constituent general assembly
  • 1963: acquisition of Laboratoires Inava (oral and dental hygiene and care products)
  • 1965: acquisition of the Klorane brand: start of the dermo-cosmetic activity
  • 1968: creation of the first Pierre Fabre Research Center at Péraudel (Castres)
  • 1969: acquisition of the Ducray brand
  • 1969: opening of the first production unit at Soual (new Castres)
The company already relied on the same strengths as it does today: complementary activities, sustained R&D investments, product safety and efficacy due to mastering their life cycle.

1970/1980

  • 1970: opening of the first international subsidiaries in Spain
  • 1973: opening of affiliates in Italy and Switzerland
  • 1974: purchase of the hydrotherapy station at Avène-les-Bains (Hérault)
  • 1974: first distribution center at Muret (near Toulouse)
  • 1976: creation of a plant extraction and fine chemical unit at Gaillac (Tarn) for the production of pharmaceutical and dermo-cosmetic active substances
  • 1978: launch of the Galénic brand
  • 1979: acquisition of the René Furterer brand
  • 1979: creation of a joint venture in Japan with Shiseido

1980/1990

  • 1980: opening of a subsidiary in Greece
  • 1982: launch of Permixon® (treatment of benign prostatic hypertrophy)
  • 1982: launch of the A-Derma brand
  • 1985: first framework contract with the CNRS
  • 1986: creation of Pierre Fabre Japan
  • 1987: opening of a dermo-cosmetic research center at Vigoulet (Toulouse) and of the skin culture center (Toulouse)
  • 1988: opening of a subsidiary in Portugal
  • 1988: launch of the Plants and Medicines brand (later to become Naturactive)
  • 1989: acquisition of the Robapharm laboratories (Switzerland)
  • 1989: creation of Pierre Fabre Oncology and launch of Navelbine®

1990/2000

  • 1990: launch of the Avène Thermal Spring Water brand
  • 1990: opening of the Immunology Research Center in Saint-Julien-en-Genevois
  • 1991: opening of the factory at Pau (for sterile injectable drugs)
  • 1992: opening of the factory at Gien (prescription products)
  • 1992: launch of Nicopatch® (for smoking cessation)
  • 1994: creation of the Klorane Institute
  • 1995: Navelbine® approved by the US health authorities
  • 1997: launch of Ixel® (depressive disorders)
  • 1999: the Pierre Fabre Foundation is recognized as being of public utility

2000/2012

  • 2001: creation of Orfagen (orphan diseases)
  • 2001: creation of the Oceanology Observatory at Banyuls-sur-Mer (partnership with Laboratoires Arago, CNRS)
  • 2001: opening of the Botanical Conservatory in Soual
  • 2002: purchase of Genesis Laboratories (Glytone® brand) in the US
  • 2005: opening up of company capital to employees
  • 2006: purchase of Darrow laboratories and brand in Brazil
  • 2007: launch of Xelevia® (diabetes) as co-marketing with Merck Sharp & Dohme-Chibret
  • 2008: agreements with Forest for the development and marketing in the North America of levomilnacipran, a molecule derived from Pierre Fabre research for the treatment of depression
  • 2008: DEFI technology, a patented packaging system that guarantees complete sterility for the product throughout use
  • 2009: Marketing Authorization for Javlor® in the treatment of the bladder cancer
  • 2009: scientific partnership with the University of Bordeaux and Bordeaux University Hospital Center for the development of a molecule for the treatment of infantile hemangioma
  • 2010: agreement with Abbott Laboratories for the development and marketing of a monoclonal antibody
  • 2010: opening of an R&D Center at the Toulouse Oncopole campus
  • 2012: construction of an Antibody Biotechnology Unit (clinical batch production) at the Research Center at Saint-Julien-en-Genevois
  • 2012: extension of the Soual factory and opening of a sterile cosmetics production unit